Role of cytogenetics in diagnosis of pediatric solid tumors md pathology exam robbins based answer
Reading File
Reading File
Finding Sources
Finding Sources
Searching PubMed
pediatric solid tumors AND molecular diagnosis
Searching the Web
WHO Classification paediatric tumours molecular genetic diagnosis solid tumors official
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Role of cytogenetics in diagnosis of pediatric solid tumors
Introduction
Pediatric solid tumors are often embryonal tumors with primitive morphology, many appearing as small round blue cell tumors. Because morphology and immunohistochemistry may overlap, cytogenetic and molecular genetic tests are important adjuncts for confirming diagnosis, classifying the tumor, estimating prognosis, detecting hereditary predisposition, and selecting targeted treatment.
Robbins notes that although many childhood tumors can be identified histologically, confirmatory molecular studies are routinely used both for diagnosis and prognostic assessment. Robbins & Kumar Basic Pathology, p. 145.
Methods used
| Method | Main utility |
|---|---|
| Conventional karyotyping | Detects numerical and structural chromosome abnormalities, balanced translocations, double minutes, and homogeneously staining regions. Requires viable dividing cells. |
| FISH | Rapid, tissue-based detection of gene amplification, deletions, and gene rearrangements. Useful on paraffin sections. |
| RT-PCR / fusion transcript assay | Detects specific fusion transcripts with high sensitivity. |
| Chromosomal microarray / SNP array | Detects copy-number changes and loss of heterozygosity (LOH). |
| NGS-based fusion panels and sequencing | Identifies cryptic rearrangements, mutations, and therapeutic targets. |
| Germline testing | Identifies inherited cancer-predisposition syndromes and guides family counseling. |
Diagnostic roles
1. Establishes or confirms the tumor type
Many pediatric sarcomas harbor characteristic, often reciprocal, chromosomal translocations producing oncogenic fusion genes. Demonstration of these rearrangements is particularly helpful when histology is equivocal.
| Tumor | Characteristic cytogenetic / molecular abnormality | Diagnostic significance |
|---|---|---|
| Ewing sarcoma | t(11;22)(q24;q12), forming EWSR1::FLI1 fusion in most tumors | Supports diagnosis of Ewing sarcoma among small round blue cell tumors. |
| Alveolar rhabdomyosarcoma | t(2;13)(q35;q14), PAX3::FOXO1; or t(1;13)(p36;q14), PAX7::FOXO1 | Identifies fusion-positive alveolar RMS and separates it from embryonal RMS. |
| Synovial sarcoma | t(X;18)(p11;q11), SS18::SSX fusion | Confirms synovial sarcoma in a monophasic spindle-cell or poorly differentiated tumor. |
| Desmoplastic small round cell tumor | t(11;22)(p13;q12), EWSR1::WT1 fusion | Characteristic for DSRCT. |
| Infantile fibrosarcoma / congenital mesoblastic nephroma | t(12;15)(p13;q25), ETV6::NTRK3 fusion | Confirms diagnosis and identifies a targetable NTRK fusion. |
| Clear cell sarcoma of soft tissue | EWSR1::ATF1 or EWSR1::CREB1 | Helps distinguish it from melanoma and other clear-cell tumors. |
Important caution: an EWSR1 break-apart FISH positivity is not specific for Ewing sarcoma, since EWSR1 rearrangement also occurs in several other tumors. A fusion-specific test and morphologic correlation are required.
In Ewing sarcoma, Robbins describes a balanced translocation involving EWSR1 on chromosome 22 and FLI1 on chromosome 11, producing a chimeric transcription factor that disrupts normal transcriptional regulation. Robbins & Kumar Basic Pathology, p. 786.
2. Resolves the differential diagnosis of small round blue cell tumors
Neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, lymphoma, retinoblastoma, and some Wilms tumors can share a small round blue cell appearance. Cytogenetics can distinguish these morphologically similar tumors.
Examples:
- EWSR1::FLI1 favors Ewing sarcoma.
- PAX3/7::FOXO1 favors alveolar rhabdomyosarcoma.
- MYCN amplification supports high-risk neuroblastoma.
- RB1 deletion/mutation supports retinoblastoma.
- WT1 abnormalities or 11p alterations support Wilms tumor in the relevant clinical and morphologic setting.
Prognostic roles
3. Risk stratification in neuroblastoma
Cytogenetic analysis is central to neuroblastoma risk grouping.
| Abnormality | Significance |
|---|---|
| MYCN amplification | Strong adverse prognostic marker, associated with aggressive disease and high-risk neuroblastoma. Detected by FISH or molecular methods. |
| 1p deletion | Associated with unfavorable outcome. |
| 11q deletion | Adverse marker, often seen in tumors without MYCN amplification. |
| 17q gain | Associated with aggressive behavior. |
| Near-triploidy / hyperdiploidy in young children | Generally associated with a better outcome than segmental chromosomal aberrations. |
FISH can demonstrate MYCN amplification as multiple amplified signals, sometimes corresponding cytogenetically to double-minute chromosomes or homogeneously staining regions. Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 307.
4. Risk assessment in Wilms tumor
Wilms tumor is associated with abnormalities of tumor-suppressor genes and chromosomal regions.
- WT1 mutation or deletion at 11p13
- Associated with WAGR syndrome and Denys-Drash syndrome.
- 11p15 abnormalities
- Linked to Beckwith-Wiedemann syndrome and altered imprinting/growth signaling.
- Loss of heterozygosity at 1p and 16q
- Associated with increased risk of relapse and adverse outcome.
- Their combined presence has been used for intensified treatment in risk-adapted protocols.
Thus, cytogenetics helps identify children who may require more intensive therapy and also identifies patients with syndromic predisposition. Robbins & Kumar Basic Pathology, pp. 148-149.
5. Prognostic subclassification of rhabdomyosarcoma
- Fusion-positive alveolar RMS with PAX3::FOXO1 or PAX7::FOXO1 has a less favorable prognosis than fusion-negative RMS.
- Cytogenetics therefore has greater prognostic value than morphology alone in some tumors originally classified as alveolar RMS.
- Embryonal RMS usually lacks these recurrent PAX-FOXO1 rearrangements.
Detection of hereditary cancer predisposition
6. Identifies germline mutations and permits family counseling
Cytogenetic and molecular testing can identify a constitutional abnormality underlying a pediatric tumor.
| Tumor | Hereditary genetic association | Clinical value |
|---|---|---|
| Retinoblastoma | Germline RB1 mutation at 13q14 | Predicts bilateral/multifocal disease, risk to siblings and offspring, and increased risk of later osteosarcoma and soft-tissue sarcoma. |
| Wilms tumor | WT1-related syndromes, WAGR, Denys-Drash, Beckwith-Wiedemann syndrome | Enables surveillance of the contralateral kidney and screening for associated anomalies. |
| Neuroblastoma | Germline ALK or PHOX2B mutations in familial cases | Enables family testing and surveillance. |
| Rhabdomyosarcoma | TP53 mutation in Li-Fraumeni syndrome, DICER1-related predisposition in selected subtypes | Guides genetic counseling and surveillance. |
In retinoblastoma, approximately 40% of cases are associated with a germline RB1 mutation; a second somatic hit in retinal progenitor cells causes tumor formation. Germline disease commonly produces bilateral tumors. Robbins & Kumar Basic Pathology, p. 122.
Predictive and therapeutic roles
7. Identifies actionable molecular targets
Cytogenetics has moved beyond diagnosis and prognosis to treatment selection.
- ETV6::NTRK3 fusion in infantile fibrosarcoma or congenital mesoblastic nephroma predicts potential response to TRK inhibitors.
- ALK alterations in neuroblastoma may allow ALK-targeted therapy in appropriate high-risk or relapsed disease.
- Specific kinase fusions may support enrollment in molecularly matched clinical trials.
This reflects the current WHO approach, which integrates histopathology with molecular pathology in classification of pediatric tumors, as outlined by the WHO pediatric tumor classification.
Limitations
- A cytogenetic abnormality should not be interpreted in isolation. Correlation with age, site, morphology, immunohistochemistry, and radiology is necessary.
- Conventional karyotyping may fail if fresh viable tumor cells are unavailable or tumor cells do not divide in culture.
- FISH identifies a targeted abnormality but may not determine the fusion partner.
- A negative result does not exclude a tumor when the test is technically limited or when an alternate fusion is present.
- Broad molecular tests may reveal variants of uncertain significance, particularly in germline testing.
Conclusion
Cytogenetics is an essential component of the diagnosis of pediatric solid tumors. Its major roles are:
- Confirming diagnosis by demonstrating tumor-specific translocations or gene fusions.
- Differentiating small round blue cell tumors with overlapping morphology.
- Providing prognostic information, especially MYCN amplification in neuroblastoma and 1p/16q LOH in Wilms tumor.
- Detecting inherited cancer predisposition, notably RB1 and WT1-related disorders.
- Guiding precision therapy by identifying actionable fusions or mutations.
Exam one-liner:
Cytogenetics in pediatric solid tumors provides diagnostic confirmation through characteristic chromosomal rearrangements, assists in differential diagnosis of small round blue cell tumors, stratifies prognosis, detects hereditary predisposition, and identifies targets for personalized therapy.
Cytogenetics in pediatric solid tumors provides diagnostic confirmation through characteristic chromosomal rearrangements, assists in differential diagnosis of small round blue cell tumors, stratifies prognosis, detects hereditary predisposition, and identifies targets for personalized therapy.
This is a shared conversation. Sign in to Orris to start your own chat.